

GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

https://marketpublishers.com/r/G5A0CCD2FC2EN.html

Date: January 2018 Pages: 0 Price: US\$ 2,500.00 (Single User License) ID: G5A0CCD2FC2EN

Abstracts

KEY FINDINGS

A global rise in infertility and increasing awareness about its effective treatments, combined with the emergence of medical tourism in fertility treatments are propelling the global infertility testing and treatment market. By the end of the forecast period of 2018 – 2026, the market is predicted to evolve at 6.39% CAGR.

MARKET INSIGHTS

The global infertility testing and treatment market is segmented on the basis of male infertility, female infertility and end-users. Both the male and female infertility markets are further sub-segmented into testing and treatment. Increasing number of couples are opting for IVF techniques, and as a result, the female infertility treatment segment is dominating the market. The end-users for this market are sub-segmented into hospitals and research laboratories, fertility and surgical centers, and cryobanks.

REGIONAL INSIGHTS

Asia-Pacific, Europe, North America and rest of the world are the markets focused for the global infertility testing and treatment market. The European market is expected to capture the highest market share by the end of the estimated period. The region has a presence of a number of IVF clinics that provide treatments at reasonable costs. The APAC market is also forecasted to exhibit a significant growth over the forecast period, driven by a low birth rate and favourable government initiatives in countries like Taiwan, South Korea, Singapore and Japan.



COMPETITIVE INSIGHTS

Major companies dealing in the infertility testing and treatment market include Endo Pharmaceuticals, Andrology Solutions, Progyny, Genea, Ferring Pharmaceuticals, Halotech DNA, Merck, Irvine Scientific, Origio, Vitrolife Ab, Ovascience, Thermo Fisher Scientific Inc, Quest Diagnostic, The Cooper Companies, Inc, Esco Micro Pte. Ltd, Alere, Elucigene, Celmatrix, Claritas Genomics, Veritas Genetics, Roche, Agilent, LabCorp, Integrated Genetics, Centogene, Phosphorus Diagnostics, Natera Inc, and Illumina Inc.



Contents

1. RESEARCH SCOPE

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA

- 2.1.1. SECONDARY DATA
- 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY

3.2. KEY FINDINGS

3.2.1. EUROPE IS THE LARGEST MARKET

3.2.2. ASIA PACIFIC IS THE FASTEST GROWING REGION IN THE INFERTILITY MARKET

3.2.3. IVF DOMINATES THE FEMALE TREATMENT MARKET

3.2.4. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

4. MARKET OVERVIEW

- 4.1. MARKET DEFINITION
- 4.2. MARKET DRIVERS AND IMPACT
- 4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
- 4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
- 4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
- 4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED THE FERTILITY TREATMENT
- 4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
- 4.2.6. HEALTHIER DONOR EGGS



4.2.7. INTRODUCTION OF NEW TESTING DEVICES

4.3. RESTRAINTS AND IMPACT

4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED

4.3.2. COUNTRY-WISE REGULATORY ISSUES

4.4. MARKET OPPORTUNITIES

4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO
INFERTILITY TREATMENTS

4.5.3.1. DIET AND SUPPLEMENTS

- 4.5.3.2. ACUPUNCTURE
- 4.5.3.3. THERAPY

4.5.3.4. QIGONG

5. INFERTILITY CAUSES

5.1. CAUSES OF MALE INFERTILITY

- 5.1.1. ABNORMALITY IN THE SPERM
- 5.1.2. ENVIRONMENTAL FACTORS
- 5.1.3. POOR HEALTH AND LIFESTYLE
- 5.2. CAUSES OF FEMALE INFERTILITY
- 5.2.1. OVULATION DISORDERS
- 5.2.2. DAMAGE TO FALLOPIAN TUBES
- 5.3. MORAL QUESTIONS

6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

- 6.1. MARKET BY MALE INFERTILITY TESTING
 - 6.1.1. DNA FRAGMENTATION
 - 6.1.2. OXIDATIVE STRESS ANALYSIS
 - 6.1.3. SPERM PENETRATION ASSAY
 - 6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
 - 6.1.5. SPERM AGGLUTINATION



- 6.1.6. MICROSCOPIC EXAMINATION
- 6.1.7. OTHERS
- 6.2. MARKET BY MALE INFERTILITY TREATMENT

6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)

- 6.2.2. SPERM RETRIEVAL TREATMENT
- 6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
- 6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
- 6.2.5. VARICOCELE REPAIRS
- 6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
- 6.2.7. INTRAUTERINE INSEMINATION (IUI)
- 6.2.8. IN VITRO FERTILIZATION (IVF)
- 6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)

7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

- 7.1. MARKET BY FEMALE INFERTILITY TESTING
 - 7.1.1. OVULATION TESTING
 - 7.1.2. HYSTEROSALPINGOGRAPHY
 - 7.1.3. LAPAROSCOPY
 - 7.1.4. TRANSVAGINAL ULTRASOUND
 - 7.1.5. OVARIAN RESERVE TESTING
 - 7.1.6. HORMONAL LEVEL TESTING
 - 7.1.7. OTHERS (GENETIC TESTING)
- 7.2. MARKET BY FEMALE INFERTILITY TREATMENT
 - 7.2.1. IN VITRO FERTILIZATION
 - 7.2.2. INTRAUTERINE INSEMINATION (IUI)
- 7.2.3. DRUG AND HORMONE THERAPIES

8. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

- 8.1. FERTILITY AND SURGICAL CENTERS
- 8.2. HOSPITALS AND RESEARCH LABORATORIES
- 8.3. CRYOBANKS

9. KEY ANALYTICS



- 9.1. PORTER'S 5 FORCE MODEL
- 9.1.1. THREAT OF NEW ENTRANTS
- 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
- 9.1.3. BARGAINING POWER OF BUYERS
- 9.1.4. BARGAINING POWER OF SUPPLIERS
- 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 9.2. VALUE CHAIN ANALYSIS
- 9.2.1. RAW MATERIAL PROCUREMENT
- 9.2.2. MANUFACTURING
- 9.2.3. SUPPLY LOGISTICS
- 9.2.4. DISTRIBUTION CHANNELS
- 9.2.5. END USERS
- 9.3. KEY BUYING CRITERIA
- 9.3.1. TREATMENT OPTIONS
- 9.3.2. QUALITY OF MEDICAL PROCEDURES
- 9.3.3. PRICE OF TREATMENTS
- 9.3.4. SHIFT TOWARDS MEDICAL TOURISM
- 9.3.5. REIMBURSEMENT
- 9.4. REGULATORY FRAMEWORK
- 9.5. KEY TRENDS
 - 9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
 - 9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
 - 9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
 - 9.5.4. REGULATORY ENVIRONMENT- KEY MARKET ENABLER
 - 9.5.5. MORE COUPLES OPTING FOR SURROGACY
- 9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
- 9.6. VENDOR LANDSCAPE
- 9.7. OPPORTUNITY MATRIX

10. KEY ANALYTICS – TESTING MARKET

- 10.1. PORTER'S 5 FORCE ANALYSIS
- 10.1.1. THREAT OF NEW ENTRANTS
- 10.1.2. THREAT OF SUBSTITUTE PRODUCTS
- 10.1.3. BARGAINING POWER OF BUYERS
- 10.1.4. BARGAINING POWER OF SUPPLIERS
- 10.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 10.2. KEY BUYING CRITERIA
- 10.3. VENDOR LANDSCAPE



10.4. OPPORTUNITY MATRIX

11. GLOBAL INFERTILITY TESTING AND TREATMENT MARKET REGIONAL ANALYSIS 2018-2026 (\$ MILLION)

11.1. NORTH AMERICA
11.1.1. US
11.1.2. CANADA
11.2. ASIA PACIFIC
11.2.1. CHINA
11.2.2. INDIA
11.2.3. JAPAN
11.2.4. SOUTH KOREA
11.2.5. REST OF ASIA-PACIFIC
11.3. EUROPE
11.3.1. UK
11.3.2. GERMANY
11.3.3. FRANCE
11.3.4. NORDICS
11.3.5. RUSSIA

11.4. REST OF THE WORLD

12. COMPETITIVE ANALYSIS

12.1. ANDROLOGY SOLUTIONS
12.1.1. OVERVIEW
12.1.2. PRODUCT PORTFOLIO
12.1.3. SCOT ANALYSIS
12.2. ENDO PHARMACEUTICALS
12.2.1. OVERVIEW
12.2.2. PRODUCT PORTFOLIO
12.2.3. STRATEGIC MOVES
12.2.4. SCOT ANALYSIS
12.3.1. OVERVIEW
12.3.2. PRODUCT PORTFOLIO
12.3.3. STRATEGIC MOVES
12.3.4. SCOT ANALYSIS
12.4. FERRING PHARMACEUTICALS



12.4.1. OVERVIEW 12.4.2. PRODUCT PORTFOLIO 12.4.3. STRATEGIC MOVES 12.4.4. SCOT ANALYSIS 12.5. GENEA 12.5.1. OVERVIEW 12.5.2. PRODUCT PORTFOLIO 12.5.3. STRATEGIC MOVES 12.5.4. SCOT ANALYSIS 12.6. HALOTECH DNA 12.6.1. OVERVIEW 12.6.2. PRODUCT PORTFOLIO 12.6.3. STRATEGIC MOVES 12.6.4. SCOT ANALYSIS **12.7. IRVINE SCIENTIFIC** 12.7.1. OVERVIEW 12.7.2. PRODUCT PORTFOLIO 12.7.3. STRATEGIC MOVES 12.7.4. SCOT ANALYSIS 12.8. MERCK 12.8.1. OVERVIEW 12.8.2. PRODUCT PORTFOLIO 12.8.3. STRATEGIC MOVES 12.8.4. SCOT ANALYSIS 12.9. ORIGIO 12.9.1. OVERVIEW 12.9.2. PRODUCT PORTFOLIO 12.9.3. STRATEGIC MOVES 12.9.4. SCOT ANALYSIS 12.10. OVASCIENCE 12.10.1. OVERVIEW 12.10.2. PRODUCT PORTFOLIO 12.10.3. STRATEGIC MOVES 12.10.4. SCOT ANALYSIS 12.11. VITROLIFE AB 12.11.1. OVERVIEW 12.11.2. PRODUCT PORTFOLIO 12.11.3. STRATEGIC MOVES

12.11.4. SCOT ANALYSIS



12.12. THERMO FISHER SCIENTIFIC INC 12.12.1. OVERVIEW 12.12.2. PRODUCT PORTFOLIO 12.12.3. STRATEGIC MOVES 12.12.4. SCOT ANALYSIS 12.13. THE COOPER COMPANIES, INC 12.13.1. OVERVIEW 12.13.2. PRODUCT PORTFOLIO 12.13.3. STRATEGIC MOVES 12.13.4. SCOT ANALYSIS 12.14. QUEST DIAGNOSTIC 12.14.1. OVERVIEW 12.14.2. PRODUCT PORTFOLIO 12.14.3. SCOT ANALYSIS 12.14.4. STRATEGIC MOVES 12.15. ESCO MICRO PTE. LTD. 12.15.1. OVERVIEW 12.15.2. PRODUCT PORTFOLIO 12.15.3. STRATEGIC MOVES 12.15.4. SCOT ANALYSIS 12.16. ELUCIGENE 12.16.1. OVERVIEW 12.16.2. PRODUCT PORTFOLIO 12.16.3. SCOT ANALYSIS 12.16.4. STRATEGIC INITIATIVE 12.17. ALERE 12.17.1. OVERVIEW 12.17.2. PRODUCT PORTFOLIO 12.17.3. SCOT ANALYSIS 12.17.4. STRATEGIC INITIATIVE 12.18. CELMATRIX 12.18.1. OVERVIEW 12.18.2. PRODUCT PORTFOLIO 12.18.3. SCOT ANALYSIS 12.18.4. STRATEGIC INITIATIVE **12.19. VERITAS GENETICS** 12.19.1. OVERVIEW 12.19.2. PRODUCT PORTFOLIO 12.19.3. SCOT ANALYSIS



12.19.4. STRATEGIC INITIATIVE **12.20. CLARITAS GENOMICS** 12.20.1. OVERVIEW 12.20.2. PRODUCT PORTFOLIO 12.20.3. SCOT ANALYSIS 12.20.4. STRATEGIC INITIATIVE 12.21. ROCHE 12.21.1. OVERVIEW 12.21.2. PRODUCT PORTFOLIO 12.21.3. SCOT ANALYSIS 12.21.4. STRATEGIC INITIATIVE 12.22. LABCORP 12.22.1. OVERVIEW 12.22.2. PRODUCT PORTFOLIO 12.22.3. SCOT ANALYSIS 12.22.4. STRATEGIC INITIATIVE 12.23. AGILENT 12.23.1. OVERVIEW 12.23.2. PRODUCT PORTFOLIO 12.23.3. SCOT ANALYSIS 12.23.4. STRATEGIC INITIATIVE **12.24. INTEGRATED GENETICS** 12.24.1. OVERVIEW 12.24.2. PRODUCT PORTFOLIO 12.24.3. SCOT ANALYSIS 12.25. PHOSPHORUS DIAGNOSTICS 12.25.1. OVERVIEW 12.25.2. PRODUCT PORTFOLIO 12.25.3. SCOT ANALYSIS 12.25.4. STRATEGIC INITIATIVE 12.26. CENTOGENE 12.26.1. OVERVIEW 12.26.2. PRODUCT PORTFOLIO 12.26.3. SCOT ANALYSIS 12.26.4. STRATEGIC INITIATIVE 12.27. NATERA INC 12.27.1. OVERVIEW 12.27.2. PRODUCT PORTFOLIO 12.27.3. SCOT ANALYSIS

GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026



12.27.4. STRATEGIC INITIATIVE 12.28. ILLUMINA INC 12.28.1. OVERVIEW 12.28.2. PRODUCT PORTFOLIO 12.28.3. SCOT ANALYSIS 12.28.4. STRATEGIC INITIATIVE



List Of Tables

LIST OF TABLES

TABLE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 (\$ MILLION) TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS TABLE 3 GLOBAL MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION) TABLE 4 GLOBAL MALE INFERTILITY TESTING MARKET 2018-2026 (\$MILLION) TABLE 5 PROS AND CONS OF DNA SHARING METHODS TABLE 6 GLOBAL DNA FRAGMENTATION MARKET BY REGION, 2018-2026 (\$MILLION) TABLE 7 GLOBAL OXIDATIVE STRESS ANALYSIS MARKET BY REGION, 2018-2026 (\$MILLION) TABLE 8 GLOBAL SPERM PENETRATION ASSAY MARKET BY REGION 2018-2026 (\$MILLION) TABLE 9 GLOBAL CASA MARKET BY REGION 2018-2026 (\$MILLION) TABLE 10 GLOBAL SPERM AGGLUTINATION MARKET BY REGION2018-2026 (\$MILLION) TABLE 11 GLOBAL MICROSCOPIC EXAMINATION MARKET BY REGION 2018-2026 (\$MILLION) TABLE 12 GLOBAL FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION) TABLE 13 GLOBAL FEMALE INFERTILITY TESTING MARKET 2018-2026 (\$MILLION) TABLE 14 COST OF OVULATION TESTING KITS IN THE US TABLE 15 GLOBAL OVULATION TESTING MARKET BY REGION 2018-2026 (\$MILLION) TABLE 16 GLOBAL HYSTEROSALPINGOGRAPHY MARKET BY REGION 2018-2026 (\$MILLION) TABLE 17 GLOBAL LAPAROSCOPY MARKET BY REGION 2018-2026 (\$MILLION) TABLE 18 GLOBAL TRANSVAGINAL ULTRASOUND MARKET BY REGION 2018-2026 (\$ MILLION) TABLE 19 GLOBAL OVARIAN RESERVE TESTING MARKET BY REGION 2018-2026 (\$MILLION) TABLE 20 GLOBAL HORMONAL LEVEL TESTING MARKET BY REGION 2018-2026 (\$ MILLION) TABLE 21 COST OF HORMONAL TEST IN THE US



TABLE 22 GLOBAL FEMALE INFERTILITY TREATMENT MARKET 2018-2026 (\$ MILLION)

TABLE 23 AVERAGE COST OF SOME INFERTILITY TREATMENTS TABLE 24 GLOBAL IVF TREATMENT MARKET BY REGION 2018-2026 (\$MILLION) TABLE 25 GLOBAL IUI TREATMENT MARKET BY REGION 2018-2026 (\$MILLION) TABLE 26 GLOBAL DRUG AND HORMONE THERAPIES MARKET BY REGION 2018-2026 (\$MILLION)

TABLE 27 SOME COMMON DRUG THERAPIES

TABLE 28 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

TABLE 29 GLOBAL FERTILITY AND SURGICAL CENTERS MARKET BY REGION 2018-2026 (\$ MILLION)

TABLE 30 GLOBAL HOSPITALS AND RESEARCH LABORATORIES MARKET BY REGION 2018-2026 (\$ MILLION)

TABLE 31 GLOBAL CRYOBANKS MARKET BY REGION 2018-2026 (\$ MILLION) TABLE 32 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET BY GEOGRAPHY 2018-2026 (\$ MILLION)

TABLE 33 NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 (\$ MILLION)

TABLE 34 SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) USING DONOR EGGS IN THE U.S. IN 2013

TABLE 35 COSTS FOR INFERTILITY TREATMENTS IN THE U.S. 2015

TABLE 36 COST OF IVF & ICSI TREATMENT, CANADA 2014

TABLE 37 ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 (\$MILLION)

TABLE 38 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 (\$MILLION)

TABLE 39 COST OF IVF IN RUSSIA



List Of Figures

LIST OF FIGURES

FIGURE 1 GLOBAL INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION) FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN FIGURE 4 RATE OF MULTIPLE DELIVERIES FIGURE 5 CAUSES OF INFERTILITY FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER FIGURE 7CAUSES OF SPERM DNA FRAGMENTATION FIGURE 8 WORLDWIDE FALLING FERTILITY RATE (TOTAL BIRTHS PER WOMAN) FIGURE 9 NUMBER OF IVF CYCLES PERFORMED IN THE US FIGURE 10 US INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 11 CANADA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 12 GROWTH IN IVF CLINICS IN ASIA FIGURE 13 CHINA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (\$MILLION) FIGURE 14 INDIA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (\$MILLION) FIGURE 15 JAPAN INFERTILITY TESTING AND TREATMENT MARKET2018-2026(MILLION) FIGURE 16 SOUTH KOREA INFERTILITY TESTING AND TREATMENT MARKET2018-2026 (MILLION) FIGURE 17 MEDICAL TOURISM IN SOUTH KOREA (\$ MILLION) FIGURE 18 REST OF ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION) FIGURE 19 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 20 FERTILITY TREATMENT IN 2014 FIGURE 21 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 22 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 23 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION)



FIGURE 24 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$MILLION) FIGURE 25 REST OF THE WORLD INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

COMPANIES MENTIONED

- 1. ANDROLOGY SOLUTIONS
- 2. ENDO PHARMACEUTICALS
- 3. PROGYNY
- 4. FERRING PHARMACEUTICALS
- 5. GENEA
- 6. HALOTECH DNA
- 7. IRVINE SCIENTIFIC
- 8. MERCK
- 9. ORIGIO
- 10. OVASCIENCE
- 11. VITROLIFE AB
- 12. THERMO FISHER SCIENTIFIC INC
- 13. THE COOPER COMPANIES, INC
- 14. QUEST DIAGNOSTIC
- 15. ESCO MICRO PTE. LTD.
- 16. ELUCIGENE
- 17. ALERE
- 18. CELMATRIX
- **19. VERITAS GENETICS**
- 20. CLARITAS GENOMICS
- 21. ROCHE
- 22. LABCORP
- 23. AGILENT
- 24. INTEGRATED GENETICS
- 25. PHOSPHORUS DIAGNOSTICS
- 26. CENTOGENE
- .27. NATERA INC
- 28. ILLUMINA INC



I would like to order

Product name: GLOBAL INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026 Product link: <u>https://marketpublishers.com/r/G5A0CCD2FC2EN.html</u>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G5A0CCD2FC2EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970